Back to today’s briefing

Story perspectives

Sarepta Halts Elevidys Shipments Amid FDA Safety Concerns

7/22/2025

45 8

Summary

Story summary

Sarepta Therapeutics has decided to halt shipments of its Elevidys gene therapy for Duchenne muscular dystrophy amid FDA concerns following three patient deaths associated with similar treatments. Initially resistant to the FDA's request, the company ultimately prioritized patient safety and regulatory compliance, with shipments set to cease by Tuesday evening.

1 of 1

Story summary

Sarepta Therapeutics has decided to halt shipments of its Elevidys gene therapy for Duchenne muscular dystrophy amid FDA concerns following three patient deaths associated with similar treatments. Initially resistant to the FDA's request, the company ultimately prioritized patient safety and regulatory compliance, with shipments set to cease by Tuesday evening.